Genetic risk for restenosis after coronary stenting

Atherosclerosis

Volumn 194, Issue 2, 2007, Pages

  Oguri, Mitsutoshi ^a   Kato, Kimihiko ^a   Hibino, Takeshi ^a   Yokoi, Kiyoshi ^a   Segawa, Tomonori ^b   Matsuo, Hitoshi ^b   Watanabe, Sachiro ^b   Nozawa, Yoshinori ^c   Murohara, Toyoaki ^d   Yamada, Yoshiji ^c,e  

^a GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^c GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e MIE UNIVERSITY   (Japan)

Author keywords

BCHE; Coronary heart disease; Genetics; GPX1; In stent restenosis; Polymorphism; ROS1

Indexed keywords

CHOLINESTERASE; GLUTATHIONE PEROXIDASE 1; INSULIN RECEPTOR; METAL; OLIGONUCLEOTIDE; ONCOPROTEIN; PROTEIN ROS1; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CORONARY ARTERY; CORONARY STENT; DIABETES MELLITUS; FEMALE; GENE PROBE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IN-STENT RESTENOSIS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

AGED; BUTYRYLCHOLINESTERASE; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE PEROXIDASE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; STENTS;

EID: 34848863000     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.12.019     Document Type: Article

References (35)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Biondi-Zoccai G.G., Agostoni P., Abbate A., et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 100 (2005) 119-123
4. Kim Y.H., Park S.W., Lee C.W., et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv 67 (2006) 181-187
5. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
6. Kereiakes D.J. Hippocrates revisited: the evidence for drug-eluting stents. Circulation 107 (2003) 3012-3014
7. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
8. Cohen D.J., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110 (2004) 508-514
9. Kong D.F., Eisenstein E.L., Sketch Jr. M.H., et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J 147 (2004) 449-456
10. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
11. Lemos P.A., Serruys P.W., and Sousa J.E. Drug-eluting stents: cost versus clinical benefit. Circulation 107 (2003) 3003-3007
12. O'Neill W.W., and Leon M.B. Drug-eluting stents: costs versus clinical benefit. Circulation 107 (2003) 3008-3011
13. Itoh Y., Mizuki N., Shimada T., et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 57 (2005) 717-729
14. Casagrande J.T., and Pike M.C. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 34 (1978) 483-486
15. Feigl P. A graphical aid for determining sample size when comparing two independent proportions. Biometrics 34 (1978) 111-122
16. Slager S.L., and Schaid D.J. Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered 52 (2001) 149-153
17. Gomma A.H., Elrayess M.A., Knight C.J., et al. The endothelial nitric oxide synthase (Glu298Asp and -786T → C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23 (2002) 1955-1962
18. Inoue T., Uchida T., Yaguchi I., et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 107 (2003) 1757-1763
19. Kastrati A., Schomig A., Seyfarth M., et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 99 (1999) 1005-1010
20. Amant C., Bauters C., Bodart J.C., et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96 (1997) 56-60
21. Mitra A.K., and Agrawal D.K. In stent restenosis: bane of the stent era. J Clin Pathol 59 (2006) 232-239
22. Virmani R., Kolodgie F.D., Farb A., et al. Drug eluting stents: are human and animal studies comparable?. Heart 89 (2003) 133-138
23. Hoffmann R., Mintz G.S., Dussaillant G.R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94 (1996) 1247-1254
24. Grewe P.H., Deneke T., Machraoui A., et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 35 (2000) 157-163
25. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
26. Neckameyer W.S., and Wang L.H. Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family. J Virol 53 (1985) 879-884
27. Birchmeier C., O'Neill K., Riggs M., et al. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci USA 87 (1990) 4799-4803
28. Zong C.S., Chan J.L., Yang S.K., et al. Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation. J Biol Chem 272 (1997) 1500-1506
29. Shiffman D., Ellis S.G., Rowland C.M., et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 77 (2005) 596-605
30. Valle A., O'Connor D.T., Taylor P.W., et al. Pseudocholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem 52 (2006) 1014-1020
31. Vionnet N., Hani E.-H., Dupont S., et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67 (2000) 1470-1480
32. Bartels C.F., Jensen F.S., Lockridge O., et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50 (1992) 1086-1103
33. Minor Jr. D.L., and Kim P.S. Measurement of the beta-sheet-forming propensities of amino acids. Nature 367 (1994) 660-663
34. Blankenberg S., Rupprecht H.J., Bickel C., et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349 (2003) 1605-1613
35. Hamanishi T., Furuta H., Kato H., et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes 53 (2004) 2455-2460